quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:00:00·59d
PRRelease
Arcus Biosciences Inc. logo

Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer

RCUS· Arcus Biosciences Inc.
Health Care
Original source

Companies

  • RCUS
    Arcus Biosciences Inc.
    Health Care

Recent analyst ratings

  • Feb 12UpdateWells Fargo$23.00
  • Jan 13UpdateGoldman$28.00
  • Jan 8UpdateMorgan Stanley$20.00
  • Feb 26UpdateH.C. Wainwright$24.00
  • Oct 21UpdateH.C. Wainwright$20.00
  • Oct 8UpdateWells Fargo$29.00

Related

  • SEC8h
    SEC Form 144 filed by Arcus Biosciences Inc.
  • SEC2d
    SEC Form DEFA14A filed by Arcus Biosciences Inc.
  • SEC2d
    SEC Form DEF 14A filed by Arcus Biosciences Inc.
  • PR2d
    Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
  • SEC3d
    Arcus Biosciences Inc. filed SEC Form 8-K: Other Events
  • PR14d
    Arcus Biosciences Announces New Employment Inducement Grants
  • SEC15d
    SEC Form 144 filed by Arcus Biosciences Inc.
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Arcus Biosciences Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022